NCT06055647View on ClinicalTrials.gov

HER-2 Expression in Pancreatic Duct Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

December 31, 2020

Conditions
Pancreatic Adenocarcinoma
Interventions
GENETIC

immunohistochemical approach

Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.

All Listed Sponsors
lead

Sohag University

OTHER

NCT06055647 - HER-2 Expression in Pancreatic Duct Adenocarcinoma | Biotech Hunter | Biotech Hunter